PRICED Act
Official title: To amend the Public Health Service Act to shorten the exclusivity period for brand name biological products from 12 to 7 years.
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Referred to the Subcommittee on Health.
Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act
This bill amends the Public Health Service Act to allow biosimilars to be marketed seven years after the reference brand name biological product is licensed. Currently, brand name biological products are provided a 12-year marketing exclusivity period.
This shortened marketing exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.
- Introduced in House Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). H.R. 6577: PRICED Act. 115th Congress. Open America. https://openamerica.io/bill/115-HR-6577/
"H.R. 6577: PRICED Act." 115th Congress, 2026, Open America, https://openamerica.io/bill/115-HR-6577/.
H.R. 6577, 115th Cong. (2026), https://openamerica.io/bill/115-HR-6577/.
[H.R. 6577: PRICED Act](https://openamerica.io/bill/115-HR-6577/)